Please assess the completion status of the following clinical trial:

Trial Title: A Randomized Double Blind Controlled Trial Comparing Sugammadex and Neostigmine After Thoracic Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects scheduled for pulmonary resection, lobectomy, pneumonectomy, bullectomy, pleurodesis~* Age 18-70 years~* American Society of Anesthesiologists (ASA) class 1, 2, 3~* Body mass Index (BMI) = 18-30 kg/m2~Exclusion Criteria:~* Subjects scheduled for esophagectomy, thoracectomy, vascular resection~* Chronic Obstructive Pulmonary Disease (COPD) Gold class III e IV, respiratory infection, asthma~* Preoperative Forced Expiratory Volume in 1 second (FEV1) \< 60% of predicted, Forced Expiratory Volume in 1 second/Forced Vital Capacity ratio (FEV1/FVC) \<70%~* Preoperative Diffusion Lung capacity for carbon monoxide/Alveolar Volume ratio (DLCO/VA) \< 60% of predicted~* Preoperative oxygen saturation (SpO2) \<92% or Partial pressure of oxygen in arterial blood/Fraction of inspired oxygen (PaO2/FiO2) ratio \<300~* Cardiovascular disease with Metabolic Equivalent of Tasks (METS) score less than 4~* Neuromuscular disorder~* Kidney failure defined as Estimated Glomerular Filtration Rate (eGFR) \< 30 ml/min/1,73 m2~* Pregnant women

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- S Group (Type: EXPERIMENTAL): Sugammadex 2 or 4 mg/kg iv once at the end of surgery
- N Group (Type: ACTIVE_COMPARATOR): Neostigmine 0.05 or 0.07 mg/kg (+ atropine 0.02 mg/kg) iv once at the end of surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).